Peptide library / MGF

MGF

Mechano growth factor commonly refers to an IGF-1 splice-variant-derived C-terminal peptide. PEG-MGF is a modified product and is not an alias for the same preparation.

Peptide & blend guide

The short version

Why people discuss it
Discussed for muscle growth and recovery after training; native MGF and PEG-MGF are distinct preparations. Community interest does not establish benefit or a suitable treatment.
What it is
Mechano growth factor commonly refers to an IGF-1 splice-variant-derived C-terminal peptide. PEG-MGF is a modified product and is not an alias for the same preparation.
Biggest caution
Endogenous splice-variant biology, a synthetic C-terminal peptide and PEG-modified products are different subjects. None can automatically borrow dosing or outcomes from IGF-1 or another analog.
Stack context
Related profiles reflect adjacent community topics or biological context. They do not establish combination benefit, compatibility or a validated regimen.

Dose and frequency reference

Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.

Sources report different amounts or schedules; the reference below is a named example, not a consensus.

Native MGF — intramuscular injection

Community reference · Not clinical guidance
Amount
200–400 mcg
Frequency
2–3 times weekly
Duration / phase
4–6 weeks

Legacy native-MGF community pattern on training days. PeptideDosages instead describes daily subcutaneous dosing for 8–12 weeks. These conflicting routes and frequencies have no established human dose-finding basis. Reference only; this does not establish safety, effectiveness or individual suitability.

Reference source · reviewed 2026-09-12

PEG-MGF — subcutaneous or intramuscular injection

Community reference · Not clinical guidance
Amount
200–400 mcg
Frequency
2–3 times weekly on training days
Duration / phase
4–6 weeks

Separate PEGylated preparation, not native MGF. This older community convention conflicts with PeptideDosages’ 200–500 mcg daily example for 8 weeks or longer.

Reference source · reviewed 2026-09-12
Compare reported schedules

Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.

Evidence & sources · Community source profile

AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.

Back to the peptide library